EASD 2019: Solvable Problems in Diabetes
Plaça de Dante, 08038 Barcelona, Spain
During the European Association of the Study of Diabetes (EASD) 2019 conference, The diaTribe Foundation will host its sixth annual program on "Solvable Problems in Diabetes." Please join us for drinks, hors d'oeuvres, and an evening of discussion on the most urgent problems and opportunities facing diabetes today.
Our event will be held at Esdeveniments Esferic, Plaça de Dante, 08038 Barcelona, Spain, a 9-minute drive (4.4 km) from the Fira Barcelona conference venue.
Doors will open at 7:00 pm for drinks, hors d'oeuvres, and mingling. We plan to start the formal program promptly at 8 pm.
This year's program will feature incredible panelists - including Professor Tina Vilsbøll of The Steno Diabetes Center Copenhagen, Professor Stephanie Amiel of King's College London, Professor Chantal Mathieu of Katholieke Universiteit Leuven, Belgium, and Professor Juliana Chan of the Hong Kong Institute of Diabetes and Obesity - who will participate in a riveting, interactive discussion moderated by The diaTribe Foundation's Kelly Close. Please see below for each panelist's biography!
For more information on "Solvable Problems in Diabetes," please email email@example.com. We look forward to seeing you in September!
We thank our sponsors for making this event possible!
Chantal Mathieu is the Professor of Internal Medicine at the University Hospital Gasthuisberg, Catholic University of Leuven, Belgium. In her role as a clinical diabetologist, Dr Mathieu is involved daily in the treatment of patients with type 1 or type 2 diabetes. Her main basic research interests focus on the pathogenesis and prevention of type 1 diabetes, as well as islet transplantation. Dr Mathieu is also active in the clinical organization of diabetes care and patient education. She is the author or co-author of more than 400 peer-reviewed research papers and she is currently the senior vice-president of the EASD. Importantly, Professor Mathieu was a co-author of 2018’s “Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range.” and the ‘ADA-EASD Consensus statement on glucose lowering therapies in T2D’. Dr Mathieu graduated from the University of Leuven as MD in 1988 and subsequently went on to study for a PhD examining pathogenetical and therapeutical aspects of immune intervention in animal models of type 1 diabetes. She coordinates the INNODIA network on biomarkers in T1D in Europe.
Tina Vilsbøll has been involved in diabetes research since 1997, and in 2004 she established the Center for Diabetes Research at Gentofte Hospital, University of Copenhagen, Denmark now part of Steno Diabetes Center Copenhagen. Her research is focused on the pathophysiology of obesity, prediabetes, type 2 diabetes (with a specific focus on insulin, glucagon and incretin hormones), regulation of appetite and food intake, and the utilisation of incretins as therapeutics. Integration of the gut in the understanding of human glucose metabolism has become a major focus in her lab over recent years. Professor Vilsbøll is an experienced teacher and supervises several PhD and medical students conducting diabetes research. She has almost 300 scientific publications (H-index 57), several published books and book chapters. Professor Vilsbøll is a frequently invited speaker at national and international meetings. In addition to her teaching and research posts, Professor Vilsbøll is a member of numerous professional societies and committees, and referees for several international journals.
Stephanie Amiel is an experimental medicine researcher with interests in the prevention and management of hypoglycaemia in diabetes treatments and the role of the brain in control of metabolism. She also conducts research in the impact of ethnicity on metabolism. Professor Amiel trained at Guy's Hospital with Professor Harry Keen and started her research career at Yale, with Professors Robert Sherwin and William Tamborlane. She led the King's team in a collaboration with Sheffield and North Tyneside in the creation of DAFNE, the UK's first national structured education program in flexible insulin therapy for adults with type 1 diabetes and continues to research in the area. With colleagues in the King's Liver Unit, she set up the King's human islet isolation and transplantation service and has developed services at King's College Hospital NHS Foundation Trust for supporting adults with Type 1 diabetes and pregnancy in diabetes. Her current research includes neuroimaging to investigate the role of the brain in hypoglycemia defenses in type 1 diabetes and in appetite control in insulin resistance and she is currently running the HARPdoc randomized controlled trial of a novel intervention for treatment-resistant hypoglycemia in adults with type 1 diabetes, looking at the impact of cognitions on hypoglycemia avoidance behaviors. Professor Amiel was awarded the Banting Memorial Lecture of Diabetes UK, the highest award bestowed by the charity, in 2013. She chaired the Guideline Development Group for the diagnosis and management of type 1 diabetes in adults, published in 2015, and currently chairs the Strategic Research Advisory Group for Diabetes UK and is a mentor on the EFSD Mentorship program.
Professor Juliana Chan is Chair Professor of Medicine and Therapeutics in the Faculty of Medicine at CUHK. She is the Founding Director of the Hong Kong Institute of Diabetes and Obesity, and Director of the CUHK-PWH International Diabetes Federation (IDF) Centre of Education and CUHK-PWH IDF Centre of Excellence in Diabetes Care. She joined CUHK in 1989. With her research team, she has set up multiple cohorts, databases and biobanks to validate a series of risk equations and discover a panel of genetic markers predictive of diabetes and its complications in Asian populations. This identifies high-risk individuals for early intervention. Patents have been awarded by the US and China Patent and Trademark Offices. She and her multidisciplinary team are devoted to the discovery, dissemination and application of knowledge in the field of diabetes and its co-morbidities in Chinese populations. Inspired by the marked benefits of team-based, protocol-driven care in clinical trial setting, she has integrated the components of structured assessment, risk stratification, personalized reporting and decision support into the first and foremost web-based Joint Asia Diabetes Evaluation® (JADE) Technology, which translates evidence into practice and evaluates the cost-effectiveness of interventions in real-world settings in Asia. Her team is now using a multidisciplinary, multiomic, multimethod approach to study the missing heritability of young-onset diabetes and genetic regulation of diabetic complications, especially kidney disease. To further address the unmet needs in diabetes, her team has received major grants and used state-of-the-art-methodologies, including various glucose and insulin clamp studies and continuous glucose monitoring, to evaluate the safety and effectiveness of novel compounds, including Chinese Medicine, and delivery systems in the field of diabetes and obesity. Professor CHAN has published more than 500 papers and 20 book chapters in her more than 30-year academic life. She is a member of the NIH-funded Global Consortium to discover genetic markers for diabetes and its complications. She sits on steering committees of multicenter outcome trials, and advisory boards for government and non-government organizations, including the World Health Organization and IDF, a global advocacy body for people with diabetes.
This listing has no upcoming events